By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

La voix des personnes atteintes d'un cancer du sein

Quel médicaments contre le cancer du sein sont offerts au Canada

Médirepère

Nom générique

Sacituzumab govitecan

Marque nominative

Trodelvy
Triple-négatif
Stade IV (métastique)
Thérapie ciblée
Gilead Sciences
médicament injectable
Alberta, Colombie britannique, Manitoba, Terre-Neuve-et-Labrador, Ontario, Québec
Nouveau-Brunswick, Nouvelle-Écosse, Territoires du nord-ouest, Nunavut, Île-du-Prince-Édouard, Saskatchewan, Yukon
Non
Approuvé par APP; Évaluation provinciale en cours
Non

Monographie du produit 

FAQ